BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hutchings HA, Alrubiay L, Watkins A, Cheung WY, Seagrove AC, Williams JG. Validation of the Crohn's and Ulcerative Colitis questionnaire in patients with acute severe ulcerative colitis. United European Gastroenterol J 2017;5:571-8. [PMID: 28588889 DOI: 10.1177/2050640616671627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 van Andel EM, Koopmann BDM, Crouwel F, Noomen CG, de Boer NKH, van Asseldonk DP, Mokkink LB. Systematic Review of Development and Content Validity of Patient-reported Outcome Measures in Inflammatory Bowel Disease: Do We Measure What We Measure? J Crohns Colitis 2020;14:1299-315. [PMID: 32211749 DOI: 10.1093/ecco-jcc/jjaa057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
2 Shen M, Meng L. Peripheral blood miR-372 as a biomarker for ulcerative colitis via direct targeting of NLRP12. Exp Ther Med 2019;18:1486-92. [PMID: 31363381 DOI: 10.3892/etm.2019.7707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]